Direct oral anticoagulants (DOACs) include dabigatran etexilate, a direct thrombin inhibitor,
and specific inhibitors of activated coagulation factor X (FXa; eg apixaban, betrixaban …

Over the past 20 years, there has been a shift from vitamin K antagonists to direct oral
anticoagulants (DOACs), which include the thrombin inhibitor dabigatran and the factor Xa …

Direct oral anticoagulants (DOACs) are widely prescribed but associated with risk of major
hemorrhage. Specific reversal agents have been developed for dabigatran (idarucizumab) …

Background The management of life-threatening bleeding in patients who are receiving
direct oral anticoagulants (DOACs) is a serious medical concern. Objective This review …

Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of
venous thromboembolism and for prevention of stroke in patients with nonvalvular atrial …

Purpose Strategies for the management of bleeding complications and facilitation of an
invasive procedure in patients receiving direct oral anticoagulants (DOACs) are reviewed …

The worldwide increase in the aging population and the associated increase in the
prevalence of atrial fibrillation and venous thromboembolism as well as the widespread use …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Essentials• There remains clinical concern regarding the optimal management of direct oral
(DOAC) anticoagulant effect for emergencies such as bleeding or urgent …

Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …